Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

be incorporated into products that are sold; even if Senomyx or its collaborators receive a regulatory approval and incorporate Senomyx flavor ingredients into products, those products may never be commercially successful; Senomyx flavor ingredients may not be useful or cost-effective for formulation into products; Senomyx or its collaborators may be unable to manufacture Senomyx flavor ingredients at commercial scale; Senomyx's ability to compete in the flavor ingredients market may decline if Senomyx does not adequately protect its proprietary technologies; and Senomyx's discovery and development programs may not be successful or result in the discovery of new flavor ingredients that are commercially viable. These and other risks and uncertainties are described more fully in Senomyx's most recently filed SEC documents, including its most recent Annual Report on Form 10-K under the headings "Risks Related to Our Business" and "Risks Related to Our Industry." All forward-looking statements contained in this press release speak only as of the date on which they were made. Senomyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Financial Information to Follow)

 

Contacts:FinancialInvestor RelationsTony Rogers

Senior Vice President and

Chief Financial OfficerGwen Rosenberg

Vice President, Investor Relations &

Corporate CommunicationsSenomyx, Inc.Senomyx, Inc.858-646-8304858-646-8369tony.rogers@senomyx.comgwen.rosenberg@senomyx.com 

 

Selected Financial InformationCondensed Statements of Operations(in thousands, except for per share amounts) Three Months
Ended December 31,Year EndedDecember 31,2012201120122011(unaudited)(unaudited)Revenues:Development revenues$

6,734$<
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Ceres, Inc. (Nasdaq: ... a U.S. patent for a genetic sequence derived from ... as research, product development and plant transformation. The company ... biosynthetic processes that are the target of a class ... companies a commercial license to the innovation, including an ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... an update on the status of the Company,s ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 3,085 and 21 shares of Series A Preferred ...
(Date:5/27/2015)... 27, 2015 ­ Caris Life Sciences®, a ... precision medicine, today announced it has appointed the Levine ... of excellence site in the Caris Centers of Excellence ... Cancer Institute is one of the largest cancer care ... new cancer patients annually. Derek Raghavan , M.D., ...
(Date:5/26/2015)... Regenestem Network has announced the grand ... Aires, Argentina. The clinic will be lead by Silvina ... assembled a multidisciplinary team of medical professionals who specialize ... Madero office. , The new Regenestem Network members ... studies in cellular therapies, and establish Regenestem protocols to ...
Breaking Biology Technology:Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3
... January 28 The Binding Site Limited,("The Binding ... company, today announces the publication of the first,international ... and management of multiple myeloma, a cancer of ... disorders. , The guidelines ...
... an announcement made recently by Astellas Pharma Inc., CV Therapeutics, ... received a letter dated November 13, 2008 from Astellas setting ... at a price of $16.00 per share, subject to due ... deliberation, with the assistance of its financial and legal advisors, ...
... PTS by Albemarle responds to the demand in ... 27 Leading specialty chemical company, Albemarle Corporation, ... company, Zymes LLC, have joined forces to scale-up ... The next generation technology promotes the clear ...
Cached Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... Bell, PA (January 7, 2013) The PATH Malaria ... MKT: INO) today announced a follow-on collaboration to ... technologies. Researchers will test whether a novel vaccine ... innovative vaccine delivery technology called electroporation could induce ...
... Researchers have identified four new regions on the human ... dangerous condition found predominantly in people with ancestors along ... this 4,000-mile network linking the Far East with Europe ... the Silk Road disease, genes. National Institutes of Health ...
... BOSTON January 8, 2013 -- As part of their ... development of obesity, Joslin Diabetes Center scientists have identified a ... major role in energy metabolism and fat storage. This ... obesity. The study is being published today ahead of print ...
Cached Biology News:MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech 2MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech 3Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 2Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 3Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 4Joslin researchers identify important factor in fat storage and energy metabolism 2